Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Takara Bio (4974 JP): Limited Upside Potential Amid Poor Financial Result and Bleak Outlook

Takara Bio (4974 JP): Takara Holdings (2531 JP)’s Tender Offer Is Light but Done

Takara Bio (4974 JP): Smaller-Than-Expected Decline in H1FY24 Profit; FY24 Guidance Revised Downward

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/takara-holdings-inc" target="_blank" data-smartkarma-citation="entities:11074:1" rel="noopener">Takara Holdings (2531 JP)</a> has launched tender offer for the ordinary shares of <a href="https://www.smartkarma.com/entities/takara-bio-inc" target="_blank" data-smartkarma-citation="entities:10766:1" rel="noopener">Takara Bio Inc (4974 JP)</a> at the price of ¥1,150 per share to acquire all the shares.</li>
<li>Currently, Takara Holdings holds 73,350,000 shares in Takara Bio, representing a controlling ownership of 60.91%. Takara Holdings plans to make Takara Bio its wholly owned subsidiary.</li>
<li>Amid bleak outlook for the operating environment, no near-term performance improvement is expected for Takara Bio. It will be wise to tender shares in the offer.</li>
</ul>



Takara Holdings (2531 JP) has launched tender offer for the ordinary shares of Takara Bio Inc (4974 JP) at the price of ¥1,150 per share to acquire all the shares.
Currently, Takara Holdings holds 73,350,000 shares in Takara Bio, representing a controlling ownership of 60.91%. Takara Holdings plans to make Takara Bio its wholly owned subsidiary.
Amid bleak outlook for the operating environment, no near-term performance improvement is expected for Takara Bio. It will be wise to tender shares in the offer.


Takara Bio (4974 JP): Timely Tender Offer from Takara Holdings (2531 JP) To Delight Shareholders